Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.

Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, Allison J, Chatham A, Raper JL, Kaslow RA, Saag MS, Mugavero MJ.

AIDS. 2008 Oct 1;22(15):1951-60. doi: 10.1097/QAD.0b013e32830efd79.

2.

Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.

HIV Clin Trials. 2005 Sep-Oct;6(5):235-45.

PMID:
16306030
3.

A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.

Juday T, Grimm K, Zoe-Powers A, Willig J, Kim E.

AIDS Care. 2011 Sep;23(9):1154-62. doi: 10.1080/09540121.2010.543884. Epub 2011 May 24.

4.

Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing.

Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C, Mugavero MJ, Allison J, Paz J, Hernandez F, Tomatis C, Saag MS, Gotuzzo E.

J Acquir Immune Defic Syndr. 2010 Feb;53(2):215-21. doi: 10.1097/QAI.0b013e3181bc0f10.

PMID:
20104120
5.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team.

JAMA. 2001 Mar 7;285(9):1155-63. Erratum in: JAMA 2001 Jun 13;285(22):2858.

PMID:
11231744
6.

Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.

Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):350-64.

PMID:
11468423
7.

Initiation of antiretroviral therapy: implications of recent findings.

Saag MS.

Top HIV Med. 2004 Jul-Aug;12(3):83-8. Review.

8.

Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.

Kazatchkine MD, Van PN, Costagliola D, Mohammed AS, Ledeine JM, Troccaz M, Belec L.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):418-24.

PMID:
11035612
9.

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.

Jarrin I, Hernández-Novoa B, Alejos B, Santos I, Lopez-Aldeguer J, Riera M, Gutiérrez F, Rubio R, Antela A, Blanco JR, Moreno S; Cohort of the Spanish HIV Research Network (CoRIS).

HIV Med. 2014 Oct;15(9):547-56. doi: 10.1111/hiv.12144. Epub 2014 Mar 24.

10.

Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.

Mocroft, Horban, Clumeck, Stellbrink, Monforte dA, Zilmer, Kirk, Gatell, Phillips, Lundgren; EuroSIDA Study Group.

HIV Clin Trials. 2006 Nov-Dec;7(6):271-84.

PMID:
17208897
11.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
12.

Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011.

Sheth AN, Ofotokun I, Buchacz K, Armon C, Chmiel JS, Hart RL, Baker R, Brooks JT, Palella FJ Jr.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):47-56. doi: 10.1097/QAI.0000000000000813.

13.
14.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
15.

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.

Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC).

AIDS. 2013 Mar 13;27(5):803-13. doi: 10.1097/QAD.0b013e32835cb997. Erratum in: AIDS. 2014 Jul 31;28(12):1853.

PMID:
23719350
17.

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535. Review.

PMID:
16625606
18.

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.

MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Lancet. 2006 Dec 16;368(9553):2125-35.

PMID:
17174704
19.

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.

HIV Med. 2005 Nov;6(6):396-402.

20.

[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].

Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F; Kliniek en Virologie van het ATHENA-project.

Ned Tijdschr Geneeskd. 2001 Aug 18;145(33):1591-7. Dutch.

PMID:
11534377

Supplemental Content

Support Center